Bristol-Celgene Megadeal Pushes 2019 Toward the Top of a Decade of Drug M&A

(Bloomberg) -- Just three days into the New Year, Bristol-Myers Squibb’s $74 billion takeover of Celgene Corp. has already propelled 2019 to the sixth-biggest year for drugmaker deals of the past d...
BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.